These findings are especially powerful since epigenetic dependencies (LSD1 or JMJD2C) in melanoma are not associated with sensitivity to BRAF inhibitors, implicating a potential therapeutic approach for patients relapsing on BRAF-targeted therapies. The gene discussed is KDM1A; the disease is melanoma.